{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:21:02Z","timestamp":1787026862615,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    With therapeutic trials on the horizon for Charcot-Marie-Tooth type 1A (CMT1A), reliable, valid, and responsive clinical outcome assessments and biomarkers are essential. Accelerate Clinical Trials in CMT (ACT-CMT) is an international study designed to address important gaps in CMT1A clinical trial readiness including the lack of a validated, responsive functional outcome measure for adults, and a lack of validated biomarkers for multicenter application in clinical trials in CMT1A. The primary aims of ACT-CMT include validation of the Charcot-Marie-Tooth Functional Outcome Measure, magnetic resonance imaging of intramuscular fat accumulation as a lower limb motor biomarker, and\n                    <jats:italic>in-vivo<\/jats:italic>\n                    reflectance confocal microscopy of Meissner corpuscle sensory receptor density, a sensory biomarker. Initial studies have indicated that these measures are feasible, reliable and valid. A large prospective, multi-site study is necessary to fully validate and examine the responsiveness of these outcome measures in relation to existing outcomes for use in future clinical trials involving individuals with CMT1A. Two hundred 15 adults with CMT1A are being recruited to participate in this prospective, international, multi-center study. Serial assessments, up to 3 years, are performed and include the CMT-FOM, CMT Exam Score-Rasch, Overall Neuropathy Limitations Scale, CMT-Health Index, as well as nerve conduction studies, and magnetic resonance imaging and Meissner corpuscle biomarkers. Correlations using baseline data will be examined for validity. Longitudinal analyses will document the changes in function, intramuscular fat accumulation, Meissner corpuscle sensory receptor density. Lastly, we will use anchor-based and other statistical methods to determine the minimally clinically important change for these clinical outcome assessments and biomarkers in CMT1A. Reliable, and responsive clinical outcome assessments of function and disease progression biomarkers are urgently needed for application in early and late phase clinical trials in CMT1A. The ACT-CMT study protocol will address this need through the prospective, longitudinal, multicenter examination in unprecedented detail of novel and existing clinical outcome assessments and motor and sensory biomarkers, and enhance international clinical trial infrastructure, training and preparedness for future therapeutic trials in CMT and related neuropathies.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2022.930435","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T01:31:12Z","timestamp":1656293472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A"],"prefix":"10.3389","volume":"13","author":[{"given":"Katy","family":"Eichinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Sowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Krischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Pareyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Shy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"B1","first-page":"97","article-title":"Charcot-Marie-Tooth disease type 1A: molecular mechanisms of gene dosage and point mutation underlying a common inherited peripheral neuropathy","volume":"26","author":"Roa","year":"1991","journal-title":"Int J Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mus.24336","article-title":"Natural history and biomarkers in hereditary sensory neuropathy type 1","volume":"51","author":"Fridman","year":"2015","journal-title":"Muscle Nerve."},{"key":"B3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10072-008-0928-z","article-title":"Relationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter study","volume":"29","author":"Padua","year":"2008","journal-title":"Neurol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10072-008-0935-0","article-title":"Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings","volume":"29","author":"Padua","year":"2008","journal-title":"Neurol Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.3390\/ijms22116048","article-title":"Emerging therapies for Charcot-Marie-tooth inherited neuropathies","volume":"22","author":"Stavrou","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"23146","DOI":"10.1074\/jbc.M109.027128","article-title":"P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy","volume":"284","author":"Nobbio","year":"2009","journal-title":"J Biol Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/mt.2013.250","article-title":"AAV1NT-3 gene therapy for charcot-marie-tooth neuropathy molecular therapy","volume":"22","author":"Sahenk","year":"2014"},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.aaa4484","article-title":"Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit","volume":"348","author":"Das","year":"2015","journal-title":"Science."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200325","article-title":"Randomized phase 2 study of ACE-083 in patients with Charcot-Marie-tooth (CMT) disease","author":"Florian","year":"2022","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"CD011952","DOI":"10.1002\/14651858.CD011952","article-title":"Ascorbic acid for the treatment of Charcot-Marie-Tooth disease","volume":"12","author":"Gess","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1474-4422(11)70025-4","article-title":"Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial","volume":"10","author":"Pareyson","year":"2011","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaneurol.2013.3178","article-title":"High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial","volume":"70","author":"Lewis","year":"2013","journal-title":"JAMA Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"146625","DOI":"10.1016\/j.brainres.2019.146625","article-title":"Are we prepared for clinical trials in Charcot-Marie-Tooth disease?","volume":"1729","author":"Rossor","year":"2020","journal-title":"Brain Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","article-title":"Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease","volume":"16","author":"Murphy","year":"2011","journal-title":"J Peripher Nerv Syst."},{"key":"B15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jns.12084","article-title":"Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis","volume":"19","author":"Sadjadi","year":"2014","journal-title":"J Peripher Nerv Syst."},{"key":"B16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ana.23572","article-title":"Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability","volume":"71","author":"Burns","year":"2012","journal-title":"Ann Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1093\/brain\/awy280","article-title":"Development and validation of the Charcot-Marie-Tooth disease infant scale","volume":"141","author":"Mandarakas","year":"2018","journal-title":"Brain."},{"key":"B18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ana.25009","article-title":"Natural history of Charcot-Marie-Tooth disease during childhood","volume":"82","author":"Cornett","year":"2017","journal-title":"Ann Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.nmd.2014.06.433","article-title":"Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective","volume":"24","author":"Johnson","year":"2014","journal-title":"Neuromuscul Disord."},{"key":"B20","first-page":"278","article-title":"Development and pilot testing of a functional outcome measure for adults with Charcot-Marie-Tooth Neuropathy (CMT-FOM)","volume":"22","author":"Eichinger","year":"2017","journal-title":"J Peripher Nerv Syst."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1381","DOI":"10.1212\/WNL.0000000000006323","article-title":"The Charcot-Marie-Tooth functional outcome measure (CMT-FOM)","volume":"91","author":"Eichinger","year":"2018","journal-title":"Nerology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/CND.0b013e31829e22e3","article-title":"Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A","volume":"15","author":"Johnson","year":"2013","journal-title":"J Clin Neuromuscul Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1474-4422(15)00242-2","article-title":"MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study","volume":"15","author":"Morrow","year":"2016","journal-title":"Lancet Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1212\/WNL.0000000000006214","article-title":"Validation and optimization of MRI-quantified calf muscle fat fraction as an outcome measure in CMT1A","volume":"22","author":"Morrow","year":"2018","journal-title":"J Peripher Nerv Syst."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1212\/01.wnl.0000282762.34274.94","article-title":"In vivo confocal microscopy of Meissner corpuscles as a measure of sensory neuropathy","volume":"69","author":"Herrmann","year":"2007","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1529-8027.2011.00342.x","article-title":"In vivo confocal microscopy of Meissner corpuscles as a novel sensory measure in CMT1A","volume":"16","author":"Almodovar","year":"2011","journal-title":"J Peripher Nerv Syst."},{"key":"B27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/jns.12406","article-title":"Reliability of the Charcot-Marie-Tooth functional outcome measure","volume":"25","author":"Bray","year":"2020","journal-title":"J Peripher Nerv Syst."},{"key":"B28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jns.2017.05.025","article-title":"In-vivo reflectance confocal microscopy of Meissner's corpuscles in diabetic distal symmetric polyneuropathy","volume":"378","author":"Creigh","year":"2017","journal-title":"J Neurol Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1212\/01.WNL.0000156517.00615.A3","article-title":"Reliability and validity of the CMT neuropathy score as a measure of disability","volume":"64","author":"Shy","year":"2005","journal-title":"Neurology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e884","DOI":"10.1212\/WNL.0000000000009035","article-title":"A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores","volume":"94","author":"Fridman","year":"2020","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1212\/01.wnl.0000286934.55620.96","article-title":"Enumerating Meissner corpuscles - Future gold standard of large fiber sensorimotor polyneuropathy?","volume":"69","author":"Dyck","year":"2007","journal-title":"Neurology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/acn3.50865","article-title":"Measuring peripheral nerve involvement in Friedreich's ataxia","volume":"6","author":"Creigh","year":"2019","journal-title":"Ann Clin Transl Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale","volume":"77","author":"Graham","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25282","article-title":"The Charcot-Marie-Tooth Health Index: evaluation of a patient-reported outcome","author":"Johnson","year":"2018","journal-title":"Ann Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/jns.12397","article-title":"Validation of the Italian version of the Charcot-Marie-Tooth Health Index","volume":"25","author":"Pisciotta","year":"2020","journal-title":"J Peripher Nerv Syst."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/ene.12783","article-title":"Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease","volume":"22","author":"Piscosquito","year":"2015","journal-title":"Eur J Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1348\/014466506X96931","article-title":"An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS)","volume":"46","author":"Pallant","year":"2007","journal-title":"Br J Clin Psychol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11136-007-9180-x","article-title":"The mathematical relationship among different forms of responsiveness coefficients","volume":"16","author":"Norman","year":"2007","journal-title":"Qual Life Res."},{"key":"B39","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An Introduction to the Bootstrap","author":"Efron","year":"1993"},{"key":"B41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/biostatistics\/kxh001","article-title":"Analyzing incomplete longitudinal clinical trial data","volume":"5","author":"Molenberghs","year":"2004","journal-title":"Biostatistics."},{"key":"B42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials."},{"key":"B43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0021-9681(86)90110-4","article-title":"Can the sickness impact profile measure change? An example of scale assessment","volume":"39","author":"MacKenzie","year":"1986","journal-title":"J Chron Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.930435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T01:31:19Z","timestamp":1656293479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.930435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":43,"alternative-id":["10.3389\/fneur.2022.930435"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.930435","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"article-number":"930435"}}